The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

Randomized, parallel-group, quadruple-blind, dose-ranging Phase II trial of psilocybin for treatment-resistant depression with three experimental dose arms (low, medium, high); psychotherapy provided alongside dosing.

Multi-centre study (sites in the United States, Canada and several European countries) assessing safety and efficacy outcomes in adults with TRD; actual enrolment reported as 233.